Description: Cymabay Therapeutics, Inc. focuses on developing therapies to treat metabolic diseases. Its lead product candidate is Arhalofenate, which completed five Phase II clinical trials for the treatment of gout. The company's product candidate also includes MBX-8025, a selective agonist that is in a Phase II clinical trial in patients with mixed dyslipidemia; and MBX-2982, an oral, G-protein coupled receptor agonist to treat type II diabetes. Cymabay Therapeutics, Inc. has a development and license agreements with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of T2DM and other disorders; and a license and development agreement with DiaTex, Inc. to develop and commercialize therapeutic products. The company was formerly known as Metabolex, Inc. Cymabay Therapeutics, Inc. was incorporated in 1988 and is based in Newark, California.
Home Page: www.cymabay.com
CBAY Technical Analysis
7575 Gateway Boulevard
Newark,
CA
94560
United States
Phone:
510 293 8800
Officers
| Name | Title |
|---|---|
| Mr. Sujal A. Shah | Pres, CEO & Director |
| Dr. Dennis D. Kim M.B.A., M.D., MBA | Chief Medical Officer |
| Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA | Chief Commercial Officer |
| Mr. Daniel Menold | VP of Fin. |
| Dr. Charles A. McWherter Ph.D. | Sr. VP, Pres of R&D and Chief Scientific Officer |
| Mr. Paul T. Quinlan | Gen. Counsel, Chief Compliance Officer & Corp. Sec. |
| Mr. Ken Boehm | Sr. VP of HR |
| Mr. Patrick J. O'Mara | Sr. VP of Bus. Devel. |
| Dr. Robert L. Martin | Sr. VP of Manufacturing & Nonclinical Devel. |
| Ms. Klara A. Dickinson-Eason | Chief Regulatory & Quality Assurance Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.7554 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2014-02-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 59 |